LQDA
Liquidia Corp
$79.47
-1.76 (-2.17%)
At close · Jul 8
Market Cap
$7.24B
Shares
88,928,099
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$79.47
Open$81.00
Day$79.19–82.96
52W$12.21–82.96
Avg vol 30d2.3M
Short int11.6M · 13.1% float · 5.1d
Short vol70%
Last earningsMay 11, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 11
Equibles Rating
blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.8 · calm
Equity put/call 0.57
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+99%
above
Price vs 50-day avg
+30%
above
RSI (14)
67
neutral
MACD trend
Negative
52-week position
95%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+24%
trailing
6-month return
+109%
trailing
YTD return
+130%
this year
Relative strength
+101%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $61 › 200d $40 — 50d above 200d
Institutional flow
Accumulating
9 of 250 funds reported for Jun 30 · net +15.8K sh shares · +5 new
Insider flow
Distributing
Net -$141.5M over 90 days · 93% sells
Short interest
Rising
13.06% of float · ▲ +16.6% MoM · 5.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
250 holders — near 3-yr high, broad support
Squeeze score
86
high risk · 0–100
Fundamentals
Revenue growth
+1031%
Y/Y
EPS growth
+51%
Y/Y
Free cash flow
$-40.0M
Valuation
P/E 479.1
rich
Balance sheet
$170.8M
net cash
Quant / Vol
risk profile
Volatility
66%
annualized · 1-yr
Max drawdown
−36%
past year
ATR
5.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
Next earnings call
Aug 9, 2026
Est · unconfirmed
· in 4 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 11, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Guidance & track record
Latest guidance
· from the Earnings Call filed Mar 31, 2026
Net revenue
· 2027
Initiated
$1B
prior FY $158.32M
midpoint +531.6% Y/Y
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+99%
Bullish
Price vs 50-day avg
+30%
Bullish
RSI (14)
67
Neutral
MACD trend
Negative
Bearish
52-week position
95%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $61 › 200d $40 — 50d above 200d
Institutional flow
Accumulating
9 of 250 funds reported for Jun 30 · net +15.8K sh shares · +5 new
Insider flow
Distributing
Net -$141.5M over 90 days · 93% sells
Short interest
Rising
13.06% of float · ▲ +16.6% MoM · 5.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
250 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $12
Now $79 · 95%
52-wk high $83
vs 200-day avg +99%
vs 50-day avg +30%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $71.2M | Q1 2026 | — |
| Patients started on treatment since launch | 3,750 | as of April 30, 2026 (since launch in June 2025) | — |
|
|
|||
| Total prescribers since launch | 980 | as of April 30, 2026 (since launch in June 2025) | — |
| Unique patient prescriptions since launch | 4,500 | as of April 30, 2026 (since launch in June 2025) | — |
|
|
|||
| annualized net revenue run rate | $0.5B | less than 1 full year on the market call | — |
| non-GAAP adjusted EBITDA non-GAAP | $71.2M | Q1 2026 call | — |
|
|
|||
| patients started on therapy | 3,750 | since launch (as of April 30) call | — |
| physicians who have prescribed YUTREPIA | 980 | since launch call | — |
| physicians who have prescribed YUTREPIA to 5 or more patients | 270 | as of April 30 (since end of February) call | — |
| unique patient prescriptions | 4,500 | since launch (as of April 30) call | — |
| YUTREPIA net product sales | $148.3M | Full year 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LQDA
this stock
Liquidia Corp
|
$7.24B | +130.4% | +1031.2% | 479.1 | 13.1% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$53.04B | +7.4% | — | — | 0.2% |
|
GALDY
Galderma Group AG/ADR
|
$50.73B | +4.9% | — | — | 0.0% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$45.13B | — | — | — | 0.0% |
|
HLN
Haleon plc
|
$42.76B | -3.6% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LQDA | -0.3% | +24.4% | +108.6% | -0.3% | +130.4% |
| SPY | -0.2% | +0.8% | +7.4% | -0.2% | +9.3% |
| vs SPY | -0.2% | +23.5% | +101.2% | -0.2% | +121.1% |
Key facts
CIK
1819576
CUSIP
53635D202
13F (30d)
12 filings
12 filers
Visit website
Investor relations